GI Partners has formed Rose BioSolutions, a cell and gene therapy leader, following its acquisition of Charles River Laboratories International’s business. The new entity combines expertise in preclinical and clinical services with advanced manufacturing capabilities across key markets. This expansion strengthens GI’s position in the biotech sector, offering clients enhanced resources and innovation.

The deal underscores growing interest in specialized life sciences solutions, signaling a shift toward integrated development platforms. Analysts note the strategic alignment of facilities in Rockville, Memphis, Northridge, and Keele, reinforcing GI’s growing footprint in drug discovery. For investors, the integration promises deeper capabilities but also requires scrutiny of operational synergies.